EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..
14th European Multidisciplinary Congress on Urological Cancers - EMUC 202210-13 November 2022 Budapest
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-002 | Simultaneous bilateral video-assisted inguinal lymphadenectomy: The best solution? | José Pereira |  Received |
 |
|||
| O-002 | Does metastases-direct therapy guided by PSMA PET/CT really improve oncologic outcomes in oligorecurrent prostate cancer patients? | Alessandro Pissavini | Received |
|
|||
| P-003 | Risk of local recurrence in men with Penile Intraepithelial Neoplasia (PeIN) in the surgical margin after penile sparing surgery | Christian Fankhauser | Received |
|
|||
| O-003 | Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum | Irene Beijert | Received |
|
|||
| O-006 | Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study | Christian Fankhauser | Received |
|
|||
| P-013 | Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/CT | Alessandro Pissavini | Received |
|
|||
| P-019 | Characterization of significant prostate cancer invisible and visible in imaging tests | Morillo Tejedor Ana Cristina | Received |
|
|||
| P-025 | Description of Castration-Resistant Prostate Cancer with Unknown Metastatic Status (CRPC-MX) population in the real-world AfrODiTA study | Alba Quesada-García | Received |
|
|||
| P-027 | Avoiding false-positive MRI results in prostate cancer-suspected men: A step forward towards reducing overdiagnosis | Mar Fernandez Salamanca | Received |
|
|||
| P-029 | Comparative study between micro-ultrasonography-guided biopsy (EXACTVUTM) and multiparametric MRI-guided biopsy (KOELISTM system) for prostate cancer diagnosis | Esther García Rojo | Received |
|
|||
| P-033 | Genomic classifiers in personalized prostate cancer radiotherapy approaches a systematic review and future perspectives based on international consensus | Simon Spohn | Received |
|
|||
| P-035 | Is cribriform pattern in biopsy a risk factor for metastatic disease on 68Ga-PSMA-PET/CT? | Joris Heetman | Received |
|
|||
| P-039 | Analysis of the evolution of a real world practice prostate cancer cohort on active surveillance | Juan Luis Sanz Miguelañez | Received |
|
|||
| P-041 | Use of BioProtect balloon in patients with low- or intermediate-risk prostate cancer receiving dose-escalated EBRT: A retrospective, single institution study reporting rectal spacing and dosimetry | Paulo Costa | Received |
|
|||
| P-042 | Location-based oncological outcomes of sentinel node dissection during radical prostatectomy: Are all sentinel nodes equal? | Alessandro Pissavini | Received |
|
|||
| P-044 | Clinical impact of ERG and PTEN alterations in men underwent radical prostatectomy | Panagiotis Velissarios Stamatakos | Received |
|
|||
| P-050 | Wait-and-see protocol in patients with biochemical recurrence after robot-assisted radical prostatectomy, with no evidence of disease on restaging PSMA PET/CT | Katelijne de Bie | Received |
|
|||
| P-052 | Genetic variants at 8q24 region are associated with prostate cancer susceptibility in a Southeastern European population | Panagiotis Vlachostergios | Received |
|
|||
| P-054 | Preliminary results from SIESTA, a pilot observational study investigating sleep quality in prostate cancer patients | Fabio Turco | Received |
|
|||
| P-055 | Correlation of claims based and patient reported pad use for incontinence one year after radical prostatectomy | Diederik Baas | Received |
|
|||
| P-058 | Long term durable effect of PectaSol-C Modified Citrus Pectin (P-MCP) treatment (tx) in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC-M0) patients (pts): Results of a prospective Phase II Study | Daniel Keizman | Received |
|
|||
| P-059 | Radical prostatectomy versus high-dose-rate brachytherapy and hypo-fractionated external beam radiation combined with long-term androgen deprivation for high-risk prostate cancer | Keiichiro Mori | Received |
|
|||
| P-064 | Retrospective observational study to assess the treatment pathway and patient journey among men who undergo radiotherapy for high-risk localised and locally advanced prostate cancer in Sweden: ODYSSEY | Megan Berger | Received |
|
|||
| P-069 | Identification of clinically significant recurrence patterns in biochemical recurrence after radical prostatectomy and first salvage treatment in patients with prostate cancer using Ga68 PSMA PET-CT | Guillermo Barbas Bernardos | Received |
|
|||
| P-070 | Pattern of local recurrence after radical prostatectomy diagnosed on PSMA PET/CT | Floor Staal | Received |
|
|||
| P-072 | A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the diagnostic performance of conventional imaging and 18F-PSMA-PET/CT | Wietske Luining | Received |
|
|||
| P-074 | Analysis of the frequency of occurrence of mutations in repair genes in patients with prostate cancer in the Republic of Bashkortostan | Alexnder Sultanbaev | Received |
|
|||
| P-075 | Local recurrence after salvage post prostatectomy radiotherapy, from palliative to potentially curative? | Guillermo Barbas Bernardos | Received |
|
|||
| P-079 | Analysis of PSA response to apalutamide in metastatic castration sensitive prostate cancer | Juan Luis Sanz Miguelañez | Received |
|
|||
| P-080 | Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study | THIERRY SCHULMANN | Received |
|
|||
| P-081 | Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study | THIERRY SCHULMANN | Received |
|
|||
| P-085 | Rash in patients treated with apalutamide in different prostate cancer settings. A real world study | Carmen Munoz Calahorro | Received |
|
|||
| P-091 | The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: The experience of 3 high-volume European centers | Alessandro Pissavini | Received |
|
|||
| P-096 | Prognostic factors in the use of immune checkpoint inhibitors for metastatic renal cell carcinoma | Hirotaka Nagasaka | Received |
|
|||
| P-099 | Tivozanib as first line treatment for metastatic renal cell carcinoma | luis cajal | Received |
|
|||
| P-101 | 3D models for surgery planning in renal cell carcinoma with venous thrombus extension. Phase II nct03738488: Predictibility | Inés Rivero Belenchón | Received |
|
|||
| P-102 | The role of cytoreductive nephrectomy in the era of immune-combination therapies: A meta-analysis | Keiichiro Mori | Received |
|
|||
| P-103 | Re-treatment with immune checkpoint inhibitors in renal cell carcinoma: A systematic review and meta-analysis | Panagiotis Vlachostergios | Received |
|
|||
| P-104 | The impact of 3D modeling in surgical planning and outcomes of partial nephrectomy | Alessandro Pissavini | Received |
|
|||
| P-105 | 3D virtual models for planning percutaneous Cryoablation of small renal masses | Alessandro Pissavini | Received |
|
|||
| P-106 | PERC-score as a nephrometry scoring system in percutaneous tumour ablation: Comparison with RENAL, mRENAL, PADUA and SPARE in a multi-centre series | Alessandro Pissavini | Received |
|
|||
| P-110 | Impact of the COVID-19 pandemic on kidney cancer care in the Netherlands | Hilin Yildirim | Received |
|
|||
| P-113 | Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LENPEMBRO) or sunitinib (SUN) in the CLEAR study | Laura Hendrickson | Received |
|
|||
| P-114 | Hereditary renal cell carcinoma surveillance protocols - a review and new surveillance protocol proposal | Miguel Miranda | Received |
|
|||
| P-118 | The impact of histology and type of energy used on oncological outcomes after local tumor ablation of small renal masses | Alessandro Pissavini | Received |
|
|||
| P-123 | Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review | Christian Fankhauser | Received |
|
|||
| P-124 | IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab | Christina ReyesWright | Received |
|
|||
| P-125 | ATM loss and therapeutic vulnerabilities in bladder cancer | Kent Mouw | Received |
|
|||
| P-131 | DNA mismatch repair testing in upper tract urothelial carcinoma patients - Is Universal Lynch Syndrome screening necessary? | Orlane Figaroa | Received |
|
|||
| P-132 | Evaluation of a cytology-molecular co-test in urine of patients with non-muscle invasive urothelial cancer | Panagiotis Vlachostergios | Received |
|
|||
| P-133 | Bladder cancer detection in urine using DNA methylation markers: A prospective preclinical validation | Irene Beijert | Received |
|
|||
| P-139 | Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy | Guenter Fingerle-Rowson | Received |
|
|||
| P-149 | Avelumab as maintenance treatment in advanced urothelial cancer in the Portuguese population: A multicentric registry analysis | Joao Gramaa | Received |
|
|||
| P-150 | Role of neutrophil-to-lymphocytes ratio in predicting non-complete response at 3 months evaluation after BCG induction in non-muscle invasive bladder cancer | Daehyuk Chung | Received |
|
|||
| P-151 | Follow-up after kidney sparing surgery in upper tract urothelial carcinoma, an overview of 10 year contemporary data; Do we need to adjust current follow up protocol? | Orlane Figaroa | Received |
|
|||
| P-152 | Prognostic value of vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma | Keiichiro Mori | Received |
|
|||
| P-160 | Urostoma APPtimize: Improving quality of life of patients having an urostomy by offering personalised and timed guidance in a patient-centred mobile application | Noor van Ginkel | Received |
|
|||
| P-162 | COVID-19 pandemic impact in bladder cancer treatment and features | José Pereira | Received |
|
|||
| P-163 | Practical approach and surgical outcome to treatment rectourinary fistula in male cancer patients | Liliya Tryfonyuk | Received |
|
|||
| LB-166 | VOLGA: Results from the phase 3 safety run-in with durvalumab (D) tremelimumab (T) enfertumab vedotin (EV) fer cisplatin-ineligible muscle-invasive bladder cancer (MIBC) | Thomas Powles | Received |
|
|||
14th European Multidisciplinary Congress on Urological Cancers - EMUC 2022
10-13 November 2022 Budapest
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 10/11/2022 TO 10/11/2023
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
